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Human Bocavirus 2 
in Children,  
South Korea
To the Editor: In 2009, Kapoor 
et al. and Arthur et al. published re-
ports on the prevalence of the newly 
identified  parvovirus,  human  bo-
cavirus 2 (HBoV-2), in fecal samples 
(1,2).  HBoV-1  had  been  discovered 
in 2005 (3), and reports indicate its 
possible  role  in  respiratory  diseases 
such as upper respiratory tract infec-
tions,  lower  respiratory  tract  infec-
tions  (LRTIs),  and  in  exacerbation 
of asthma (4); in these diseases, the 
virus co-infects with other respiratory 
viruses  (5).  Systemic  infection  with 
HBoV-1 and possible association of 
this virus with other diseases such as 
gastroenteritis, Kawasaki disease, and 
hepatitis  have  been  reported  (6–8). 
We  looked  for  HBoV-2  in  clinical 
samples  from  children  with  various 
diseases, including acute LRTIs, Ka-
wasaki  disease,  Henoch-Schönlein 
purpura, and hepatitis.
During September 2008–January 
2009, a total of 212 nasopharyngeal 
aspirates  were  collected  from  212 
children (median age 8 months, range 
1–59 months) hospitalized with acute 
LRTIs  at  Sanggyepaik  Hospital  in 
Seoul, South Korea. Previously, dur-
ing January 2002–June 2006, a total of 
173 serum samples had been obtained 
from children (age range 1 month–15 
years) with hepatitis (hepatitis B, 20 
samples;  hepatitis  C,  11  samples; 
unknown hepatitis, 31 samples), Ka-
wasaki disease (12 samples), and He-
noch-Schönlein purpura (18 samples) 
and from healthy children (same age 
range, 81 samples) (9). The study was 
approved by the internal review board 
of Sanggyepaik Hospital. 
DNA was extracted from serum 
samples,  and  RNA  and  DNA  were 
extracted  from  nasopharyngeal  aspi-
rates by using a QIAamp Viral RNA 
Mini Kit (QIAGEN, Hilden, Germa-
ny) and a QIAamp DNA Blood Mini 
Kit  (QIAGEN  GmbH),  respectively. 
All  nasopharyngeal  aspirates  were 
tested  by  PCR  for  common  respira-
tory viruses such as respiratory syncy-
tial virus, influenza viruses A and B, 
parainfluenza  virus,  and  adenovirus, 
as  described  previously  (10).  PCRs 
to detect HBoV-1 were performed by 
using  primers  for  the  nonstructural 
(NS) 1 and nucleocapsid protein (NP) 
1 genes, as described previously (10). 
Additional  PCRs  for  rhinovirus,  hu-
man metapneumovirus, human coro-
navirus  (hCoV)-NL63,  hCoV-OC43, 
hCoV-229E, hCoV HKU-1, WU poly-
omavirus, and KU polyomavirus were 
performed, as described, for HBoV-2
–positive samples (10).
HBoV-2  was  detected  by  per-
forming first-round PCR with primers 
based on the NS gene, HBoV2-sf1, and 
HBoV2-sr1. Second-round PCR was 
performed by using primers HBoV2-
sf2  and  HBoVsr2,  as  described  pre-
viously (1). The PCR products were 
sequenced by using an ABI 3730 XL 
autoanalyzer  (Applied  Biosystems, 
Foster  City,  CA,  USA).  The  nucle-
otide sequences were aligned by us-
ing BioEdit 7.0 (www.mbio.ncsu.edu/
BioEdit/BioEdit.html)  and  presented 
in a topology tree, prepared by using 
MEGA 4.1 (www.megasoftware.net). 
Of  the  212  samples  tested,  the 
following viruses were detected: hu-
man  respiratory  syncytial  virus  (in 
124 [58.4%] samples), human rhino-
virus (24 [11.3%]), influenza virus A 
(18 [8.4%]), adenovirus (10 [4.7%]), 
and  parainfluenza  virus  (8  [3.7%]). 
HBoV-1 was not detected in the study 
population. HBoV-2 DNA was found 
in 5 (2.3%) of the 212 samples collect-
ed; all positive samples had been ob-
tained in October 2008. The age range 
of the children with HBoV-2–positive 
samples  was  4–34  months  (median 
24 months), and all were male. The 
diagnoses  were  bronchiolitis  for  3 
children and bronchopneumonia for 2. 
The most frequently codetected virus 
was human respiratory syncytial virus, 
found in 4 (80%) of 5 samples. One 
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sample that was negative for respira-
tory  syncytial  virus  and  positive  for 
HBoV-2 was negative for all other re-
spiratory viruses. 
Nucleotide  sequences  were  de-
termined for the NS-1 gene, and phy-
logenetic  analyses,  which  included 
HBoV-3, a new lineage designated by 
Arthur et al. (2), showed that the NS-1 
gene was relatively well conserved and 
that there were 2 major groups of the 
virus, the UK strain and the Pakistan 
strain. HBoV-2 strains isolated from 
South Korea belonged to the HBoV-
PK2255 (FJ170279) cluster (Figure). 
Recent  studies  have  detected 
HBoV-1 in serum samples of children 
with Kawasaki disease and of an im-
munocompromised  child  with  hepa-
titis (7,8). However, neither HBoV-1 
nor HBoV-2 was detected in the 172 
serum samples from 61 patients with 
hepatitis, 12 with Kawasaki disease, 
18  with  Henoch-Schönlein  purpura, 
and 81 healthy children.
The  absence  of  HBoV-1  in  the 
samples examined was unexpected be-
cause HBoV-1 was detected in >10% 
of 558 respiratory samples collected 
from a demographically similar study 
population during the winter 2 years 
earlier (10). Future studies, with larger 
populations and over longer periods, 
are needed to delineate seasonal varia-
tions between HBoV-1 and HBoV-2.
We demonstrated HBoV-2 DNA 
in  the  respiratory  tract  secretions  of 
children  with  acute  LRTIs.  In  most 
positive samples, the virus was found 
in addition to other respiratory viruses. 
A limitation is that the study did not 
consider health control measures and 
other clinical disease such as gastro-
enteritis and was conducted for a short 
time. The role of HBoV-2 in LRTIs 
remains  unclear;  further  studies  are 
needed to clarify whether this virus is 
only shed from the respiratory tract or 
whether it replicates in the gastrointes-
tinal tract. 
This study was partly supported by 
a research grant (2008) from Inje Univer-
sity.
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Figure.  Phylogenetic  analysis  of  nonstructural  (NS)  1  gene  sequences  from  human 
bocavirus 2 strains from Korea (KR), United Kingdom (UK), and Pakistan (PK), presented 
on  a  topology  tree  prepared  by  using  MEGA  3.1  (www.megasoftware.net).  Nucleotide 
alignment of a 417-bp portion of the NS-1 gene was prepared by using BioEdit 7.0 (www.
mbio.ncsu.edu/BioEdit/BioEdit.html).  The  nucleotide  distance  matrix  was  generated  by 
using the Kimura 2-parameter estimation. Nodal confidence values indicate the results 
of  bootstrap  resampling  (n  =  1,000).  Five  strains  from  South  Korea  (FJ771028–32) 
are in boldface. Scale bar indicates estimated number of substitutions per 10 bases. LETTERS
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Nontuberculous  
Mycobacterium  
Infection and  
Tumor Necrosis 
Factor-α  
Antagonists 
To  the  Editor:  Mycobacterium 
haemophilum  is  an  aerobic,  slow-
growing  microorganism  with  optimal 
growth at 30°C to 32°C. It has a unique 
requirement for ferric iron–containing 
compounds (1), from which it acquired 
its  name  (i.e.,  haemophilum).  Infec-
tions  with  M.  haemophilum  are  rare, 
but cervicofacial lymphadenitis caused 
by M. haemophilum has been described 
in  children  (2).  Besides  cervicofacial 
lymphadenitis, extrapulmonary signs of 
M. haemophilum disease include sub-
cutaneous noduli, arthritis, and osteo-
myelitis, which generally affect immu-
nocompromised patients (3). Recently, 
2 cases of cutaneous M. haemophilum 
infections after alemtuzumab treatment 
were reported (4). A small number of 
pulmonary M. haemophilum infections 
associated with AIDS or solid organ or 
bone marrow transplantation have been 
described  (1).  We  report  pulmonary 
M. haemophilum infection in a wom-
an  who  had  been  immunosuppressed 
by tumor necrosis factor-α antagonist 
(TNF-αA) (adalimumab) treatment for 
rheumatoid arthritis.
A 72-year-old woman with a his-
tory  of  rheumatoid  arthritis  and  ob-
structive  sleep  apnea  syndrome  had 
signs and symptoms of fatigue, mild 
fever  episodes,  and  a  nonproductive 
cough  9  months  after  treatment  for 
rheumatoid  arthritis  had  begun  with 
methotrexate  (MTX)  and  TNF-αA. 
Physical examination was unremark-
able except for a body temperature of 
38.9°C. Laboratory testing showed an 
increased  erythrocyte  sedimentation 
rate (ESR) (77 mm/h), an increased C-
reactive protein (CRP) level (60 mg/L), 
a normal leukocyte count (8,500 cells/
μL), and relative monocytosis (12%). 
HIV  serologic  testing  results  were 
negative. Chest radiograph showed an 
infiltrate in the right upper lobe. Chest 
computed tomography confirmed this 
finding and showed lymphadenopathy 
in the right hilus and mediastinum.
Notably, the tuberculin skin test 
result  was  negative  at  screening  be-
fore she began the TNF-αA treatment, 
but was now positive (20 mm), sug-
gesting  mycobacterial  infection. Au-
ramine and Ziehl-Neelsen staining of 
sputum  and  bronchoalveolar  liquids 
showed  no  acid-fast  bacilli,  and  M. 
tuberculosis  infection  was  not  con-
firmed  by  PCR  or  culture.  Eventu-
ally, a mediastinal lymph node biopsy 
was  taken  by  endoscopic  ultrasound 
guidance.  Granulomatous  inflamma-
tion  and  acid-fast  bacilli  were  seen 
by  microscopy.  Corresponding  cul-
tures yielded a strain identified as M. 
haemophilum at the Netherlands Na-
tional Institute for Public Health and 
the Environment (RIVM) by using the 
Inno-LiPA  Mycobacteria  v2  reverse 
line blot assay (Innogenetics, Ghent, 
Belgium).  Strain  identity  was  con-
firmed by sequencing of the complete 
16S rDNA gene, which was identical 
to that of M. haemophilum available 
in  the  GenBank  sequence  database 
(National  Center  for  Biotechnology 
Information;  www.ncbi.nlm.nih.gov; 
accession no. X88923).
The RIVM performed drug sus-
ceptibility testing by using a modi-
fied agar dilution method (5). Mid-
dlebrook 7H10 media were enriched 
with  10%  sheep  blood  hemolyzed 
by 1:1 dilution with water and sub-
sequent  freezing–thawing.  Historic 
drug susceptibility data was reviewed 
(Table).  Initially,  adalimumab  was 
discontinued,  and  our  patient  was 
treated with isoniazid, ethambutol, ri-
fampin, and pyrazinimide because M. 
tuberculosis infection was suspected. 
After  identification  of  M.  haemo-
philum, our patient was treated with 
rifampin  and  azithromycin.  A  total 
treatment duration of 10 months re-
sulted in complete resolution of the 
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Table. Antimicrobial drug susceptibility test results for Mycobacterium haemophilum
isolate from rheumatoid arthritis patient and other M. haemophilum isolates* 
Case report  RIVM historic data (n = 49)  Antimicrobial
drug Classification  MIC, mg/L  % Susceptible  % Resistant 
Isoniazid Resistant 10 0 100
Rifampin Susceptible 0.2 4 96
Ethambutol Resistant 20 0 100
Streptomycin  Susceptible <1.0 35 65
Cycloserine  Susceptible 50 78 22
Prothionamide Susceptible <1.0 61 39
Amikacin Resistant 10 29 71
Ciprofloxacin Resistant 4.0 88 12
Clofazimine Susceptible <0.5 92 8
Clarithromycin  Susceptible <2.0 94 6
Rifabutin Susceptible <0.2 96 4
*All isolates submitted to the Mycobacteria Reference Laboratory, National Institute for Public Health 
and the Environment (RIVM), the Netherlands, January 2000–January 2007. Before January 2004, 
strains tested were identified by 16S rDNA gene sequencing; after January 2004, strains were 
identified by the Inno-LiPA assay (Innogenetics, Ghent, Belgium). 